PMID

Data

Article Title

Organization

Synthesis and biological activity of some partially modified retro-inverso analogues of cholecystokinin.

Centre De Pharmacologie-Endocrinologie (Montpellier, France)

Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted 1,4-benzodiazepin-2-amines.

Merck Sharp & Dohme Research Laboratories

Synthesis and biological activities of pseudopeptide analogues of the C-terminal heptapeptide of cholecystokinin. On the importance of the peptide bonds.

TBA

Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubility.

TBA

Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.

Merck Sharp & Dohme Research Laboratories

 

Conversion of acyclic nonpeptide CCK antagonists into CCK agonists

Glaxo Wellcome Research and Development

An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.

Predix Pharmaceuticals

A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely.

Mayo Clinic and Foundation

Synthesis and biological activity of CCK heptapeptide analogues. Effects of conformational constraints and standard modifications on receptor subtype selectivity, functional activity in vitro, and appetite suppression in vivo.

Abbott Laboratories

N-methylated analogs of Ac[Nle28,31]CCK(26-33): synthesis, activity, and receptor selectivity.

Hadassah-University Hospital